Block Copolymer Nanoparticles for Sustained Antibody Expression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current genetic medicine delivery systems, such as adeno-associated viruses (AAVs) struggle to deliver large genetic payloads or multiple payloads effectively, often triggering immune responses and are not biocompatible, while non-viral systems like liposomes are easily degraded and difficult to engineer.

Innovation Solution

A composition of polymer nanoparticles formed by block copolymers, comprising poly-2-(dimethylamino)ethyl methacrylate and poly-monomethyl methacrylate or poly-vinyl methacrylate, which can complex with nucleic acids to deliver therapeutic genes, allowing expression of full-length antibodies in target tissues.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If adeno-associated viruses (AAVs) are used for genetic medicine delivery, then delivery efficiency to target tissues is improved, but immune responses are triggered and payload size is limited

Engineering Contradiction:

Improvedelivery efficiencyVSAvoidimmune response

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses polymer nanoparticles as an intermediary delivery vehicle instead of viral vectors. The block copolymer forms nanoparticles that complex with nucleic acids through electrostatic interactions, serving as a non-viral mediator to deliver genetic payloads without triggering immune responses against viral capsids

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the physical and chemical parameters of the delivery system by using synthetic block copolymers with specific molecular weights and compositions. The first block has Mw ≥20,000 Da for structural integrity, while the second block provides nucleic acid complexing capability, creating nanoparticles with optimized properties for in vivo delivery

Inventive Principle:

Principle #35Parameter changes

2Reliability

If adeno-associated viruses (AAVs) are used for genetic medicine delivery, then delivery efficiency is improved, but payload size capacity is limited

Engineering Contradiction:

Improvedelivery efficiencyVSAvoidpayload size

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The polymer nanoparticle delivery system provides universal capacity to accommodate multiple types of nucleic acid payloads including large genetic sequences, plasmid DNA, and multiple therapeutic genes simultaneously, without the size constraints of viral capsids

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Object-affected harmful factors

If non-viral gene delivery systems like liposomes are used, then immune response is reduced, but biocompatibility is poor and engineering is difficult

Engineering Contradiction:

Improveimmune responseVSAvoidengineering capability

Core Design Contradiction:

Object-affected harmful factorsVSEase of manufacture

Solution Approach 1:

The patent creates composite block copolymer structures combining two distinct polymer blocks with complementary functions. The first block provides structural framework with high molecular weight (≥20,000 Da), while the second block provides nucleic acid interaction capabilities, creating a composite material that is both biocompatible and easily engineered

Inventive Principle:

Principle #40Composite materials

4Object-affected harmful factors

If non-viral gene delivery systems like liposomes are used, then immune response is reduced, but stability against enzymatic degradation is poor

Engineering Contradiction:

Improveimmune responseVSAvoidenzymatic stability

Core Design Contradiction:

Object-affected harmful factorsVSStability of the object's composition

Solution Approach 1:

The patent employs biodegradable block copolymers that are designed to be stable during circulation and delivery but degrade into harmless components after fulfilling their delivery function. The polymer blocks are constructed from biocompatible monomers that can be metabolized by the body, providing temporary protection against enzymatic degradation while maintaining eventual biocompatibility

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The polymer nanoparticles enable efficient, sustained expression of antibodies in target tissues, overcoming immune response issues and providing prolonged persistence, with better stability and affordability compared to exogenous antibody administration.

Implementation Method 1

Methodology Applied

Scientific EffectElectrostatic interaction: Electrostatics

Data Source

PatentUS12458606B2Polymer nanoparticle compositions for in vivo expression of polypeptides

Publication Date: 2025.11.04 BATTELLE MEMORIAL INST

AI summary

The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.